



**GlycoMimetics, Inc.**

**Innovation Today, Healing Tomorrow.**

## **GlycoMimetics to Present at Four Investor Conferences This Month**

March 7, 2018

ROCKVILLE, Md.--(BUSINESS WIRE)--Mar. 7, 2018-- GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will present at four investor conferences during the month of March, including:

### **30th Annual ROTH Conference**

*March 11 – 14, 2018, The Ritz Carlton, Dana Point, CA*  
CFO Brian Hahn will present on March 12 at 3:30 p.m. PT.

### **Cowen 38th Annual Health Care Conference**

*March 11 – 14, 2018, Copley Place Marriott, Boston, MA*  
CEO Rachel King will present on March 14 at 9:20 a.m. ET.

### **BioCentury: 25th Annual Future Leaders in the BioTech Industry**

*March 23, 2018, Millennium Broadway Hotel & Conference Center, New York, NY*  
Mrs. King will present in room 311 at 2:30 p.m. ET.

### **Needham & Company's 17th Annual HealthCare Conference**

*March 27 – 28, 2018, Westin Grand Central Hotel, New York, NY*  
Mrs. King will present on March 27 at 8:00 a.m. ET.

### **About GlycoMimetics, Inc.**

GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is currently being evaluated in a Phase 1 clinical trial for the treatment of multiple myeloma. The FDA granted GMI-1271 Breakthrough Therapy designation for the treatment of adult AML patients with relapsed/refractory disease. GlycoMimetics has also recently initiated a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at [www.glycomimetics.com](http://www.glycomimetics.com).

View source version on businesswire.com: <http://www.businesswire.com/news/home/20180307005331/en/>

Source: GlycoMimetics, Inc.

For GlycoMimetics, Inc.

#### **Investors:**

Shari Annes, 650-888-0902

[sannes@annesassociates.com](mailto:sannes@annesassociates.com)

or

#### **Media:**

Jamie Lacey-Moreira, 410-299-3310

[jamielacey@presscommpr.com](mailto:jamielacey@presscommpr.com)